These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31824189)

  • 41. Inclusion body myositis.
    Dimachkie MM; Barohn RJ
    Semin Neurol; 2012 Jul; 32(3):237-45. PubMed ID: 23117948
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sporadic Inclusion Body Myositis: A Clinicopathological Study.
    Challa S; Jakati S; Narla S; Uppin MS; Kannan MA; Jagarlapudi MKM
    Neurol India; 2021; 69(3):638-641. PubMed ID: 34169859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic Accuracy of Anti-CN1A on the Diagnosis of Inclusion Body Myositis. A Hierarchical Bivariate and Bayesian Meta-analysis.
    Mavroudis I; Knights M; Petridis F; Chatzikonstantinou S; Karantali E; Kazis D
    J Clin Neuromuscul Dis; 2021 Sep; 23(1):31-38. PubMed ID: 34431799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis.
    Tasca G; Monforte M; De Fino C; Kley RA; Ricci E; Mirabella M
    Muscle Nerve; 2015 Dec; 52(6):956-62. PubMed ID: 25808807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two emerging phenotypes of atypical inclusion body myositis: illustrative cases.
    Salam S; Morrow JM; Howard R; Miller JAL; Quinlivan RM; Machado PM
    Clin Exp Rheumatol; 2023 Mar; 41(2):340-347. PubMed ID: 36861744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Inflammatory myopathies].
    Schoser B
    Z Rheumatol; 2009 Oct; 68(8):665-75; quiz 676-7. PubMed ID: 19756663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MODERN ASPECTS OF ETIOPATHOGENESIS, DIAGNOSIS, CLINICAL COURSE AND TREATMENT OF SPORADIC INCLUSION BODY MYOSITIS.
    Shakarishvili R; Kvirkvelia N; Nikolaishvili I; Nebadze E
    Georgian Med News; 2020 Jan; (298):80-83. PubMed ID: 32141855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of anti-NT5c1A autoantibody in Korean patients with inflammatory myopathies.
    Lee SA; Lee HJ; Suh BC; Shin HY; Kim SW; Yoon BA; Choi YC; Park HJ
    PLoS One; 2023; 18(4):e0284409. PubMed ID: 37058449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inclusion body myositis and dysphagia. Presentation, intervention and outcome at a swallowing clinic.
    Shrivastava M; Harris C; Holmes S; Brady S; Winter S
    J Laryngol Otol; 2023 Feb; 137(2):213-218. PubMed ID: 35234119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physiological Mechanisms and Associated Pathophysiology of Dysphagia in Older Adults.
    Estupiñán Artiles C; Regan J; Donnellan C
    Gerontol Geriatr Med; 2022; 8():23337214221142949. PubMed ID: 36582660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dysphagia--pathophysiology, diagnosis and treatment.
    Cecconi E; Di Piero V
    Front Neurol Neurosci; 2012; 30():86-9. PubMed ID: 22377871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Rare Case of Sporadic Inclusion Body Myositis (s-IBM).
    Acharya S; Shukla S; Kitey P; Khan S; Mahajan SN
    J Clin Diagn Res; 2016 Jan; 10(1):OD07-8. PubMed ID: 26894112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sporadic inclusion body myositis and hereditary inclusion body myopathy.
    Simmons Z; Towfighi J
    J Clin Neuromuscul Dis; 2002 Mar; 3(3):122-32. PubMed ID: 19078666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myositis-related autoantibody profile and clinical characteristics stratified by anti-cytosolic 5'-nucleotidase 1A status in connective tissue diseases.
    Diederichsen LP; Iversen LV; Nielsen CT; Jacobsen S; Hermansen ML; Witting N; Cortes R; Korsholm SS; Krogager ME; Friis T
    Muscle Nerve; 2023 Jul; 68(1):73-80. PubMed ID: 37177880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inclusion body myositis and associated diseases: an argument for shared immune pathologies.
    Nelke C; Kleefeld F; Preusse C; Ruck T; Stenzel W
    Acta Neuropathol Commun; 2022 Jun; 10(1):84. PubMed ID: 35659120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis.
    Giannini M; Fiorella ML; Tampoia M; Girolamo F; Fornaro M; Amati A; Lia A; Abbracciavento L; D'Abbicco D; Iannone F
    Rheumatology (Oxford); 2021 Mar; 60(3):1234-1242. PubMed ID: 32911543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein aggregation in inclusion body myositis, a sporadic form among protein aggregate myopathies, and in myofibrillar myopathies--a comparative study.
    Bastian A; Goebel HH
    Rom J Intern Med; 2010; 48(4):377-84. PubMed ID: 21528768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inclusion body myositis--a review.
    Vogel H
    Adv Anat Pathol; 1998 May; 5(3):164-9. PubMed ID: 9868522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies.
    Mirabella M; Alvarez RB; Bilak M; Engel WK; Askanas V
    J Neuropathol Exp Neurol; 1996 Jul; 55(7):774-86. PubMed ID: 8965093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Swallowing therapy for dysphagia in acute and subacute stroke.
    Bath PM; Lee HS; Everton LF
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD000323. PubMed ID: 30376602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.